Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: Results of the Third National Acute Spinal Cord Injury randomized controlled trial

JAMA

Volumn 277, Issue 20, 1997, Pages 1597-1604

  Bracken, Michael B ^a   Shepard, Mary Jo ^b   Holford, Theodore R ^b   Leo Summers, Linda ^b   Aldrich, E Francois ^b   Fazl, Mahmood ^b   Fehlings, Michael ^b   Herr, Daniel L ^b   Hitchon, Patrick W ^b   Marshall, Lawrence F ^b   Nockels, Russ P ^b   Pascale, Valentine ^b   Perot, Phanor L ^b   Piepmeier, Joseph ^b   Sonntag, Volker K H ^b   Wagner, Franklin ^b   Wilberger, Jack E ^b   Winn, H Richard ^b   Young, Wise ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; PLACEBO; TIRILAZAD;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; MULTICENTER STUDY; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSATION; SEPSIS; SPINAL CORD INJURY;

EID: 1642422176     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.20.1597     Document Type: Article

References (36)

1. Bracken MB, Freeman DH, Hellenbrand K. Incidence of acute traumatic hospitalized spinal cord injury in the United States, 1970-77. Am J Epidemiol. 1981;113:615-622.
2. Collins WF, Piepmeier J, Ogle E. The spinal cord injury problem: a review. Cent Nerv Syst Trauma. 1986;3:317-331.
3. Bracken MB, Collins WF. Randomized clinical trials of spinal cord injury treatment. In: Becker DP, Polishock JT, eds. Central Nervous System Trauma, Status Report, 1985. Washington, DC: National Institute of Neurological Disorders and Stroke; 1985.
4. Bracken MB, Collins WF, Freeman DF, et al. Efficacy of methylprednisolone in acute spinal cord injury. JAMA. 1984;251:45-52.
5. Bracken MB, Shepard MJ, Hellenbrand KG, et al. Methylprednisolone and neurological function one year after spinal cord injury. J Neurosurg. 1985;63:704-713.
6. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-1411.
7. Bracken MB, Shepard MJ, Collins WF Jr, et al. Methylprednisolone or naloxone treatment after acute spinal cord injury: 1 year follow-up data: results of the second National Acute Spinal Cord Injury Study. J Neurosurg. 1992;76:23-31.
8. Holford TR, Bracken MB. A model for estimating level and net severity of spinal cord injuries. Stat Med. 1992;2:1171-1186.
9. Bracken MB, Holford TR. Effect of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg. 1993;79:500-507.
10. Otani K, Abe H, Kadoya S, et al. Beneficial effect of methylprednisolone sodium succinate in the treatment of acute spinal cord injury. Sekitsui Sekizui J. 1994;7:633-647.
11. Chiles BW III, Cooper PR. Acute spinal cord injury. N Engl J Med. 1996;334:514-520.
12. Hsu CY, Dimitrijevic MR. Methylprednisolone in spinal cord injury: the possible mechanism of action. J Neurotmuma. 1990;7:115-119.
13. Hall ED. The neuroprotective pharmacology of methylprednisolone. J Neurosurg. 1992;76:13-22.
14. Anderson DK, Dugan LL, Means ED, Horrocks LA. Methylprednisolone and membrane properties of primary cultures of mouse spinal cord. Brain Res. 1994;637:119-125.
15. Hall ED. Neuroprotective actions of glucocorticoid and non-glucocorticoid steroids in acute neuronal injury. Cell Molec Neurobiol. 1993;13:415-432.
16. Constantini S, Young W. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg. 1994;80:97-111.
17. Hall ED. Effects of the 21-aminosteroid U74006F on post traumatic spinal cord ischemia in cats. J Neurosurg. 1988;68:462-465.
18. Anderson DK, Braughler JM, Hall ED, et al. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg. 1988;69:562-567.
19. Hall ED, Yonkers PA, Horan KL, Braughler JM. Correlation between attenuation of posttraumatic spinal cord ischemia and preservation of tissue vitamin E by the 21-aminosteroid U74006F: evidence for an in vivo antioxidant mechanism. J Neurotrauma. 1989;6:169-176.
20. Anderson DK, Hall ED, Braughler JM, McCall JM, Means ED. Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. J Neurotrauma. 1991;8:187-192.
21. Holtz A, Gerdin B. Efficacy of 21-aminosteroid U-74006F in improving neurological recovery after spinal cord injury in rats. Neurol Res. 1992;14:44-52.
22. Hall ED, McCall JM, Means ED. Therapeutic potential of the lazaroids in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol. 1994;28:221-268.
23. American Spinal Injury Association. Standards for Neurological and Functional Classification of Spinal Cord Injury. rev ed. Chicago, I11: American Spinal Injury Association; 1992.
24. Hamilton BB, Granger CV, Sherwin FS, et al. A uniform national data system for medical rehabilitation. In: Fuhrer MJ, ed. Rehabilitation Outcomes: Analysis and Measurement. Baltimore, Md: Paul H Brookes; 1987:137-147.
25. Braughler JM, Hall ED. Lactate and pyruvate metabolism in the injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. J Neurosurg. 1983;59:256-261.
26. SAS Institute Inc. SAS/STAT User's Guide. Cary, NC: SAS Institute Inc; 1988.
27. Braughler JM, Hall ED. Effects of multidose methylprednisolone sodium succinate administration on injured cat spinal cord neurofilament degradation and energy metabolism. J Neurosurg. 1984; 61:290-295.
28. Hall ED, Wolf DL, Braughler JM. Effects of a single large dose of methylprednisolone sodium succinate on experimental posttraumatic spinal cord ischemia: dose-response and time-action analysis. J Neurosurg. 1984;61:124-130.
29. Braughler JM, Hall ED, Means ED, et al. Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg. 1987;67:102-105.
30. Sadrzadeh SMH, Anderson DK, Panter SS, et al. Hemoglobin potentiates central nervous system damage. J Clin Invest. 1987;79:662-664.
31. Sano K, Asano T, Tanashima T, et al. Lipid peroxidation as a cause of cerebral vasospasm. Neurol Res. 1980;2:253-272.
32. Kassell NF, Haley EC, Apperson-Hansen C, Alves WM. Randomized, double blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg. 1996;84:221-228.
33. Demopoulos HB, Flamm ES, Pietronigro DD, et al. The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand. 1980;492(suppl 3):91-119.
34. Hall ED, Braughler JM. Free radicals in CNS injury. In: Waxman S, ed. Molecular and Cellular Approaches to the Treatment of Brain Diseases. New York, NY: Raven Press; 1993:81-105.
35. Hall ED, Yonkers PA, Taylor BA, Sun FF. Lack of effect of post-injury treatment with methylprednisolone or tirilazad mesylate on eicosanoid levels in the acutely injured cat spinal cord. J Neurotrauma. 1995;12:245-258.
36. Xu J, Qu ZX, Hogan EL, Perot PL Jr. Protective effect of methylprednisolone on vascular injury in rat spinal cord injury. J Neurotrauma. 1992; 9:245-253.